HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin.

Abstract
The authors report three cases of Raynaud phenomenon that developed during doxorubicin, bleomycin, and vincristine (ABV) therapy for acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma. Although Raynaud phenomenon is well documented as a side effect of bleomycin, vinblastine, and cisplatin chemotherapy for germ cell neoplasms, it has not been widely documented in patients with AIDS.
AuthorsC F von Gunten, E L Roth, J H Von Roenn
JournalCancer (Cancer) Vol. 72 Issue 6 Pg. 2004-6 (Sep 15 1993) ISSN: 0008-543X [Print] United States
PMID7689922 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Bleomycin
  • Vinblastine
  • Doxorubicin
Topics
  • Acquired Immunodeficiency Syndrome (complications)
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bleomycin (administration & dosage, adverse effects)
  • Doxorubicin (administration & dosage, adverse effects)
  • HIV Seropositivity (complications)
  • Humans
  • Male
  • Raynaud Disease (chemically induced)
  • Sarcoma, Kaposi (complications, drug therapy)
  • Vinblastine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: